Addex Regains Nasdaq Listing Compliance
November 08, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Announces Participation in the Bio-Europe 2023 Conference
November 02, 2023 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Completes ADS Ratio Change
October 20, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Announces Plan to Implement ADS Ratio Change
October 06, 2023 16:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
September 20, 2023 01:00 ET
|
Addex Therapeutics
Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 -...
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
September 05, 2023 01:00 ET
|
Addex Therapeutics
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
September 04, 2023 01:00 ET
|
Addex Therapeutics
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-stroke functional recovery Ad Hoc Announcement Pursuant to...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 10, 2023 01:00 ET
|
Addex Therapeutics
ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendationIndivior GABAB PAM collaboration extended to June 2024...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
August 04, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...